Scientific Advisory Board
Gareth Evans MD FCRP
Professor in Med Genetics and Cancer Epi, University of Manchester
Professor in Med Genetics and Cancer Epi, University of Manchester Professor Evans has established a national and international reputation in clinical and research aspects of cancer genetics, particularly in neurofibromatosis and breast cancer. He has developed a clinical service for cancer genetics in the North West Region of England, which is nationally regarded. He has published 808 peer reviewed research publications; 290 as first or senior author. He has published over 130 reviews and chapters and has had a book published by Oxford University Press on familial cancer. He has an ISI web of knowledge H-index of 106 and a google scholar H-index of 144 having only published his first article in 1990. In the last 5 years he has raised over £35 million in grants for multicentre and local studies – approximately £31 million to Manchester. He has led a successful bid for a Nationally funded NF2 service (£7.5 million pa) that started in 2010 and is involved in the national complex NF1 service. He is theme lead and cancer lead on the All Manchester NIHR Biomedical Research Centre worth £28.5 Million (2016-2020).
Justin T. Jordan, MD MPH
Clinical Director, MGH Pappas Center for Neuro-Oncology, Massachusetts General Hospital
Dr. Jordan earned his bachelor's degree in biology in 2004 from Texas Christian University, then his MD from the University of Texas Medical School in Houston. During that time he performed basic science and translational research on brain tumor immunology at the University of Texas M.D. Anderson Cancer Center in Houston. He then completed his neurology residency at the University of Texas Southwestern Medical Center in Dallas, where he served as chief resident. He trained in the neuro-oncology fellowship at the joint program of Massachusetts General Hospital, Dana Farber Cancer Institute, and Brigham and Women's Hospital. In his second year of fellowship, he concentrated on translational research in the neurofibromatosis and allied disorders, and completed a Masters of Public Health degree at the Harvard T.H. Chan School of Public Health. He joined the clinical faculty of the Pappas Center for Neuro-Oncology and the Family Center for Neurofibromatosis in 2015, and became Clinical Director of the MGH Brain Tumor Center in July 2017 and Director of the Neurofibromatosis Clinic in February 2020.
Michel Kalamarides, MD, PhD
Professor of Neurosurgery and Chairman of the Department of Surgery, Research and Innovation in Pitie-Salpetriere Hospital
Michel Kalamarides, MD, PhD, is Professor of Neurosurgery and Chairman of the Department of Surgery, Research and Innovation in Pitie-Salpetriere Hospital – Sorbonne University in Paris, France. He is a group leader in the team « Genetic and Development of brain tumors », part of the INSERM U1127 at the Brain and Spine Institute (Piti-Salpetriere). Its research group is working on meningioma, particularly using mouse models to dissect the mechanisms of meningioma initiation and progression.
He is an expert in vestibular schwannoma and meningioma surgery. He is leading the French NF2 reference clinical center and the French NF2 network and is active in the NF2 international network. He is an ad-hoc reviewer for many journals and is a member of many societies including the French society of Neurosurgery and the AANS.
Matthias A. Karajannis, MD, MS
Pediatric Neuro-Oncologist, Memorial Sloan Kettering
Dr. Karajannis is a pediatric neuro-oncologist who has cared for children with brain tumors, spinal cord tumors, and neurofibromatosis for 11 years and currently serves as Chief of Neuro-Oncology Service Service at Memorial Sloan Kettering. Dr. Karajannis received his MS from New York University School of Medicine and MD from Free University Berlin as well as residency and fellowships at Duke University Medical Center (Pediatrics) and MSK (Pediatric Hematology/Oncology & Pediatric Neuro-Oncology), respectively. His research focuses on translating findings from the laboratory into better ways to diagnose and treat children and young adults with brain tumors. Dr. Karajannis is currently the principal investigator of several early-phase clinical trials for patients with neurofibromatosis, with the goal of finding new treatment strategies for this inheritable condition that predisposes people to multiple nervous-system tumors. He is also actively involved as an investigator in cooperative clinical trial groups including the Children’s Oncology Group and Pediatric Brain Tumor Consortium.
Garry Cutter, MD
Professor Emeritus of Biostatistics in the UAB School of Public Health in the Department of Biostatistics
Dr. Cutter has a major interest in design, analysis and interpretation of clinical trials, epidemiologic studies and evaluation research. He has directed numerous coordinating centers of multiple NIH randomized trials: most recently the Early Biomarkers of Autism Spectrum Disorders in Infants with Tuberous Sclerosis Complex and the randomized Preventing Epilepsy Using Vigabatrin in Infants with Tuberous Sclerosis (PREVeNT trial) both NINDS funded studies. He has been the Deputy Director of the Operations Center and Director of the Coordinating Center for Neurofibromatosis Consortium. He directed the coordinating center for the NHLBI Chronic Hypertension in Pregnancy (CHAP) and the Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE) clinical trial funded by NHLBI. He was the PI of the completed Trial of Thymectomy plus Prednisone versus Prednisone alone in the treatment of non-thymomatous Myasthenia Gravis (MGTx). He is the immediate past Director of the NARCOMS multiple sclerosis patient registry and the Myasthenia Gravis patient registry. He is the Director, Biostatistics/Bioinformatics Resource (BBR) Core in the O’Brien Center for Acute Kidney Injury Research, UAB-USC (NIDDK), UAB (NIAID) and Associate Director, National Center for High Impact Clinical Trials in Rehabilitation Medicine. He is a recent past President of the Consortium of MS Centers.
He is a member of numerous data and safety monitoring committees for the NIH, Pharmaceutical Companies and foundations as well as advisory committees. He served on the International Clinical Trials Committee of the National MS Society and International Federation of MS Societies for over a decade as well as being on the editorial board of the journal MS and is a contributing editor for the journal Neurology Clinical Practice as a contributing editor. He is an Associate Editor of Alzheimer’s Disease Translational Research. He is a member of the Statistics Editorial Board for the Journal of the American Society of Nephrology (JASN). He is a mentor on numerous K awards, PhD and master’s students and teaches in various national and international short courses.